<p>Lake Street Capital 的研究分析師在週五向投資者發佈的研究報告中開始覆蓋 OncoCyte（NASDAQ:OCX - 獲取免費報告）股票。該公司給予該股票 &#34;買入&#34; 評級，並設定了 5.00 美元的目標價。Lake Street Capital 的目標價表明，相較於公司之前的收盤價，潛在上漲幅度為 55.28%。</p>
<p>其他幾位股票研究分析師也最近對 OCX 發表了看法。Stephens 在週二重申了 &#34;持平&#34; 評級，並對 OncoCyte 的股票設定了 4.00 美元的目標價。Needham &amp; Company LLC 在週二重申了 &#34;買入&#34; 評級，並設定了 4.25 美元的目標價。最後，StockNews.com 在 1 月 13 日的報告中開始覆蓋 OncoCyte 股票，並給予該公司 &#34;賣出&#34; 評級。一位分析師對該股票給予了賣出評級，一位給予了持有評級，三位給予了買入評級。根據 MarketBeat 的數據，OncoCyte 目前的平均評級為 &#34;持有&#34;，共識目標價為 4.56 美元。</p>
<p><strong>閲讀我們最新的 OCX 研究報告</strong></p>
<h2>OncoCyte 股票上漲 1.3%</h2>
<p>OncoCyte 股票週五開盤價為 3.22 美元。OncoCyte 的 52 周低點為 1.92 美元，52 周高點為 4.75 美元。該公司的 50 日移動平均價格為 2.77 美元，200 日移動平均價格為 2.73 美元。公司的市值為 5620 萬美元，市盈率為 -0.73，貝塔值為 0.79。</p>
<p>OncoCyte（NASDAQ:OCX - 獲取免費報告）最近於 3 月 24 日發佈了季度財報。公司報告每股收益（EPS）為 0.48 美元，超出市場共識預期的 -0.40 美元，超出幅度為 0.88 美元。OncoCyte 的淨利潤率為 -6122.29%，股本回報率為 -269.32%。該季度的營業收入為 149 萬美元，而分析師預期為 16 萬美元。整體來看，股票研究分析師預測 OncoCyte 本財年的每股收益將為 -2.57 美元。</p>
<h2>內部人士買賣</h2>
<p>在相關消息中，首席財務官 Andrea S. James 於 2 月 7 日星期五購買了 97,561 股公司的股票。該股票的平均購買成本為每股 2.05 美元，總價值為 200,000.05 美元。收購完成後，首席財務官現在持有 151,231 股公司的股票，價值 310,023.55 美元。此次交易使其持股增加了 181.78%。該交易已在向 SEC 提交的文件中披露，相關信息可通過 SEC 網站獲取。此外，主要股東 Patrick W. Smith 於 2 月 7 日星期五購買了 1,077,600 股公司的股票。該股票的平均購買成本為每股 2.05 美元，總交易額為 2,209,080.00 美元。購買後，該內部人士現在直接持有 2,872,671 股公司股票，價值約 5,888,975.55 美元。這筆交易使其持股增加了 60.03%。該購買的披露信息可在此處找到。過去 90 天內，內部人士共購買了價值 2,430,510 美元的 1,185,625 股公司股票。內部人士持有公司股票的比例為 1.58%。</p>
<h2>機構投資者對 OncoCyte 的看法</h2>
<p>幾家對沖基金最近調整了對公司的持股。Geode Capital Management LLC 在第三季度將其在 OncoCyte 的持股增加了 12.2%。Geode Capital Management LLC 目前持有 103,980 股公司股票，價值 296,000 美元，此前在上個季度購買了額外的 11,289 股。FNY Investment Advisers LLC 在第四季度將其在 OncoCyte 的持股增加了 15.1%。FNY Investment Advisers LLC 目前持有 49,377 股公司股票，價值 117,000 美元，此前在此期間購買了額外的 6,481 股。Pura Vida Investments LLC 在第四季度將其在 OncoCyte 的持股增加了 32.1%。Pura Vida Investments LLC 目前持有 654,451 股公司股票，價值 1,558,000 美元，此前在上個季度購買了額外的 159,106 股。Two Sigma Securities LLC 在第四季度獲得了 OncoCyte 的新股份，價值 31,000 美元。最後，Broadwood Capital Inc. 在第四季度將其在 OncoCyte 的持股增加了 26.7%。Broadwood Capital Inc. 目前持有 6,244,405 股公司股票，價值 14,862,000 美元，此前在上個季度購買了額外的 1,315,339 股。55.35% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 OncoCyte</h2>
<p>（獲取免費報告）</p>
<p>OncoCyte Corporation 是一家精準診斷公司，專注於在美國和國際上開發和商業化專有檢測。該公司正在開發 DetermaIO，一種基因表達檢測，用於評估腫瘤微環境以預測對免疫療法的反應；DetermaCNI，一種用於監測癌症患者治療效果的血液監測工具；以及 VitaGraft，一種用於監測血液基礎的實質性器官移植的檢測。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 OncoCyte</li>
<li>三隻可以提升您投資組合的家居改善股票</li>
<li>購買 Chewy 股票反轉？這是現在的理由</li>
<li>股票拆分意味着什麼？</li>
<li>Ibotta 股票：為什麼回購看起來像是一個看漲的賭注</li>
<li>百分比收益者告訴投資者什麼，以及為什麼它們沒有告訴全部故事</li>
<li>Joby Aviation 股票：分析師信心與聰明資金一致</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 OncoCyte 嗎？</h2>
<p>在您考慮 OncoCyte 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 OncoCyte 並不在名單上。</p>
<p>雖然 OncoCyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMDX

<p>Lake Street Capital 已經開始對 OncoCyte (NASDAQ:OCX) 進行覆蓋，給予 “買入” 評級，目標價為 5.00 美元，意味着潛在上漲幅度為 55.28%。其他分析師的評級則各有不同，平均共識為 “持有”，目標價為 4.56 美元。OncoCyte 的股票開盤價為 3.22 美元，52 周範圍為 1.92 美元至 4.75 美元。該公司報告每股收益為 0.48 美元，超出預期。內部人士購買活動增加，首席財務官 Andrea S. James 和主要股東 Patrick W. Smith 進行了大量購買</p>

<p>Research analysts at Lake Street Capital initiated coverage on shares of OncoCyte (NASDAQ:OCX - Get Free Report) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The firm set a &#34;buy&#34; rating and a $5.00 price target on the stock. Lake Street Capital's price target indicates a potential upside of 55.28% from the company's previous close.</p>
<div class="lb-trans"><p>Lake Street Capital 的研究分析師在週五向投資者發佈的研究報告中開始覆蓋 OncoCyte（NASDAQ:OCX - 獲取免費報告）股票。該公司給予該股票 &#34;買入&#34; 評級，並設定了 5.00 美元的目標價。Lake Street Capital 的目標價表明，相較於公司之前的收盤價，潛在上漲幅度為 55.28%。</p>
</div><p>Several other equities research analysts also recently weighed in on OCX. Stephens reissued an &#34;equal weight&#34; rating and issued a $4.00 price target on shares of OncoCyte in a report on Tuesday. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $4.25 target price on shares of OncoCyte in a research report on Tuesday. Finally, StockNews.com assumed coverage on shares of OncoCyte in a report on Monday, January 13th. They issued a &#34;sell&#34; rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, OncoCyte presently has an average rating of &#34;Hold&#34; and a consensus price target of $4.56.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也最近對 OCX 發表了看法。Stephens 在週二重申了 &#34;持平&#34; 評級，並對 OncoCyte 的股票設定了 4.00 美元的目標價。Needham &amp; Company LLC 在週二重申了 &#34;買入&#34; 評級，並設定了 4.25 美元的目標價。最後，StockNews.com 在 1 月 13 日的報告中開始覆蓋 OncoCyte 股票，並給予該公司 &#34;賣出&#34; 評級。一位分析師對該股票給予了賣出評級，一位給予了持有評級，三位給予了買入評級。根據 MarketBeat 的數據，OncoCyte 目前的平均評級為 &#34;持有&#34;，共識目標價為 4.56 美元。</p>
</div><p><strong>Read Our Latest Research Report on OCX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 OCX 研究報告</strong></p>
</div><h2>OncoCyte Stock Up 1.3 %</h2>
<div class="lb-trans"><h2>OncoCyte 股票上漲 1.3%</h2>
</div><p>Shares of OncoCyte stock opened at $3.22 on Friday. OncoCyte has a 52-week low of $1.92 and a 52-week high of $4.75. The firm's 50 day moving average price is $2.77 and its 200-day moving average price is $2.73. The company has a market cap of $56.20 million, a P/E ratio of -0.73 and a beta of 0.79.</p>
<div class="lb-trans"><p>OncoCyte 股票週五開盤價為 3.22 美元。OncoCyte 的 52 周低點為 1.92 美元，52 周高點為 4.75 美元。該公司的 50 日移動平均價格為 2.77 美元，200 日移動平均價格為 2.73 美元。公司的市值為 5620 萬美元，市盈率為 -0.73，貝塔值為 0.79。</p>
</div><p>OncoCyte (NASDAQ:OCX - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.88. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.16 million. As a group, equities research analysts forecast that OncoCyte will post -2.57 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>OncoCyte（NASDAQ:OCX - 獲取免費報告）最近於 3 月 24 日發佈了季度財報。公司報告每股收益（EPS）為 0.48 美元，超出市場共識預期的 -0.40 美元，超出幅度為 0.88 美元。OncoCyte 的淨利潤率為 -6122.29%，股本回報率為 -269.32%。該季度的營業收入為 149 萬美元，而分析師預期為 16 萬美元。整體來看，股票研究分析師預測 OncoCyte 本財年的每股收益將為 -2.57 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In related news, CFO Andrea S. James purchased 97,561 shares of the firm's stock in a transaction on Friday, February 7th. The stock was bought at an average cost of $2.05 per share, with a total value of $200,000.05. Following the completion of the acquisition, the chief financial officer now owns 151,231 shares of the company's stock, valued at $310,023.55. The trade was a 181.78 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Patrick W. Smith acquired 1,077,600 shares of the company's stock in a transaction dated Friday, February 7th. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $2,209,080.00. Following the purchase, the insider now directly owns 2,872,671 shares in the company, valued at approximately $5,888,975.55. This trade represents a 60.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 1,185,625 shares of company stock valued at $2,430,510 over the last 90 days. Insiders own 1.58% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Andrea S. James 於 2 月 7 日星期五購買了 97,561 股公司的股票。該股票的平均購買成本為每股 2.05 美元，總價值為 200,000.05 美元。收購完成後，首席財務官現在持有 151,231 股公司的股票，價值 310,023.55 美元。此次交易使其持股增加了 181.78%。該交易已在向 SEC 提交的文件中披露，相關信息可通過 SEC 網站獲取。此外，主要股東 Patrick W. Smith 於 2 月 7 日星期五購買了 1,077,600 股公司的股票。該股票的平均購買成本為每股 2.05 美元，總交易額為 2,209,080.00 美元。購買後，該內部人士現在直接持有 2,872,671 股公司股票，價值約 5,888,975.55 美元。這筆交易使其持股增加了 60.03%。該購買的披露信息可在此處找到。過去 90 天內，內部人士共購買了價值 2,430,510 美元的 1,185,625 股公司股票。內部人士持有公司股票的比例為 1.58%。</p>
</div><h2>Institutional Investors Weigh In On OncoCyte</h2>
<div class="lb-trans"><h2>機構投資者對 OncoCyte 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of OncoCyte by 12.2% in the 3rd quarter. Geode Capital Management LLC now owns 103,980 shares of the company's stock valued at $296,000 after purchasing an additional 11,289 shares in the last quarter. FNY Investment Advisers LLC raised its stake in shares of OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company's stock worth $117,000 after buying an additional 6,481 shares during the period. Pura Vida Investments LLC lifted its position in shares of OncoCyte by 32.1% during the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company's stock valued at $1,558,000 after buying an additional 159,106 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in OncoCyte in the 4th quarter valued at $31,000. Finally, Broadwood Capital Inc. increased its holdings in OncoCyte by 26.7% in the 4th quarter. Broadwood Capital Inc. now owns 6,244,405 shares of the company's stock worth $14,862,000 after acquiring an additional 1,315,339 shares in the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對公司的持股。Geode Capital Management LLC 在第三季度將其在 OncoCyte 的持股增加了 12.2%。Geode Capital Management LLC 目前持有 103,980 股公司股票，價值 296,000 美元，此前在上個季度購買了額外的 11,289 股。FNY Investment Advisers LLC 在第四季度將其在 OncoCyte 的持股增加了 15.1%。FNY Investment Advisers LLC 目前持有 49,377 股公司股票，價值 117,000 美元，此前在此期間購買了額外的 6,481 股。Pura Vida Investments LLC 在第四季度將其在 OncoCyte 的持股增加了 32.1%。Pura Vida Investments LLC 目前持有 654,451 股公司股票，價值 1,558,000 美元，此前在上個季度購買了額外的 159,106 股。Two Sigma Securities LLC 在第四季度獲得了 OncoCyte 的新股份，價值 31,000 美元。最後，Broadwood Capital Inc. 在第四季度將其在 OncoCyte 的持股增加了 26.7%。Broadwood Capital Inc. 目前持有 6,244,405 股公司股票，價值 14,862,000 美元，此前在上個季度購買了額外的 1,315,339 股。55.35% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About OncoCyte</h2>
<div class="lb-trans"><h2>關於 OncoCyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.</p>
<div class="lb-trans"><p>OncoCyte Corporation 是一家精準診斷公司，專注於在美國和國際上開發和商業化專有檢測。該公司正在開發 DetermaIO，一種基因表達檢測，用於評估腫瘤微環境以預測對免疫療法的反應；DetermaCNI，一種用於監測癌症患者治療效果的血液監測工具；以及 VitaGraft，一種用於監測血液基礎的實質性器官移植的檢測。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than OncoCyte</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
<li>What Does a Stock Split Mean?</li>
<li>Ibotta Stock: Why the Buyback Looks Like a Bullish Bet</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Joby Aviation Stock: Analyst Confidence and Smart Money Align</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 OncoCyte</li>
<li>三隻可以提升您投資組合的家居改善股票</li>
<li>購買 Chewy 股票反轉？這是現在的理由</li>
<li>股票拆分意味着什麼？</li>
<li>Ibotta 股票：為什麼回購看起來像是一個看漲的賭注</li>
<li>百分比收益者告訴投資者什麼，以及為什麼它們沒有告訴全部故事</li>
<li>Joby Aviation 股票：分析師信心與聰明資金一致</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OncoCyte Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 OncoCyte 嗎？</h2>
</div><p>Before you consider OncoCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 OncoCyte 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 OncoCyte 並不在名單上。</p>
</div><p>While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 OncoCyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lake Street Capital 的分析師開始對 OncoCyte（NASDAQ:OCX）進行覆蓋